Celldex’s Promising Clinical Data and Strategic Development Plans Drive Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00.

Sam Slutsky has given his Buy rating due to a combination of factors related to Celldex’s promising clinical data and strategic development plans. The company’s recent Phase 1 trial results for their CDX-622 bispecific antibody indicate a differentiated safety and pharmacodynamic profile, particularly in targeting mast cells. This positions the asset uniquely for respiratory conditions where TSLP and mast cells are implicated, such as asthma.
Furthermore, the treatment has demonstrated a favorable safety profile with no dose-limiting toxicities or serious adverse events, which is consistent with preclinical toxicology studies. The observed sustained decrease in serum tryptase, a marker often associated with efficacy in related treatments, also supports the potential of CDX-622. These factors, combined with Celldex’s ongoing and planned clinical trials, contribute to the positive outlook and Buy rating from the analyst.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $42.00 price target.